DocDollars

Amarin Pharma, Inc.

NJ · United States · Reporting entity ID 100000010379

Total reported 2019–2025
$26.9M
#263 of 2,960 reporting companies — 0% of all reported industry payments
$18.0M in general payments across 429,428 records, plus $8.82M in research funding across 256 records.

How it breaks down

General payments $18,036,277
Research funding $8,823,085

Where this comes from

Figures are from the CMS Open Payments “payments grouped by reporting entity” dataset, queried live. Reporting entities are applicable manufacturers and group purchasing organisations required to report under the Sunshine Act.

Summary

Amarin Pharma, Inc. reported $26.9M to US doctors and teaching hospitals from 2019 to 2025, ranking #263 of 2,960 reporting companies. 33% of that was research funding and 67% general payments such as consulting, speaking, food and travel. 429,428 general payment records and 256 research records were filed.

Common questions about Amarin Pharma, Inc.

How much has Amarin Pharma, Inc. paid US doctors?

Amarin Pharma, Inc. reported $26,859,363 to US physicians and teaching hospitals across the 2019–2025 Open Payments program years: $18,036,277 in general payments, $8,823,085 in research funding.

How does Amarin Pharma, Inc. rank among drug and device companies?

It ranks #263 of 2,960 reporting entities by total reported value, about 0% of all industry payments in the dataset.

Does a payment from Amarin Pharma, Inc. mean a doctor did something wrong?

No. Open Payments records transfers of value such as speaking fees, consulting, meals, travel and research funding. The data shows the relationship, not its effect on prescribing or care.